Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Rare Tumor × palbociclib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 149 Neoplasm Metastasis 22 Neoplasms 17 Sarcoma 10 Ovarian Neoplasms 10 Squamous Cell Carcinoma of Head and Neck 8 Pancreatic Neoplasms 8 Carcinoma, Non-Small-Cell Lung 7 Endometrial Neoplasms 6 Colorectal Neoplasms 6 Prostatic Neoplasms 5 Melanoma 5 Lymphoma, Non-Hodgkin 5 Head and Neck Neoplasms 5 Breast Diseases 5 Sarcoma, Ewing 4 Recurrence 4 Multiple Myeloma 4 Medulloblastoma 4 Lung Neoplasms 4 Carcinoma, Renal Cell 4 Triple Negative Breast Neoplasms 3 Rhabdomyosarcoma 3 Rhabdoid Tumor 3 Precursor Cell Lymphoblastic Leukemia-Lymphoma 3 Osteosarcoma 3 Neuroblastoma 3 Liposarcoma 3 Leukemia, Myeloid, Acute 3 Glioblastoma 3

Interventions

sintilimab 1 pyrotinib 1 palbociclib 1 niraparib 1 dacomitinib 1 aumolertinib 1 atezolizumab 1 alectinib 1 Vemurafenib 1 Imatinib Mesylate 1 Crizotinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04423185 2025-02-11

PLATFORM Study of Precision Medicine for Rare Tumors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting

Rare Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡